910462-33-8 Usage
Uses
Used in Pharmaceutical Industry:
4-(3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)propyl)morpholine is used as a synthetic intermediate for the development of pharmaceutical compounds. Its unique reactivity and structural features allow it to be a key component in the synthesis of new drugs, potentially leading to the discovery of novel therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, 4-(3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)propyl)morpholine is utilized as a building block for the creation of new agrochemicals. Its ability to form complexes and participate in chemical reactions makes it a valuable asset in the design of innovative pesticides or other agricultural chemicals.
Used in Materials Science:
4-(3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)propyl)morpholine is employed as a component in the development of advanced materials. Its potential to engage in various chemical reactions and form stable complexes can contribute to the creation of new materials with unique properties for use in a range of applications, from electronics to environmental technologies.
Used in Organic Synthesis:
As a versatile boronic acid derivative, 4-(3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)propyl)morpholine is used as a reagent in organic synthesis. Its capacity to participate in reactions such as Suzuki-Miyaura cross-coupling makes it a valuable tool for the formation of new organic compounds, including those with potential applications in medicine, agriculture, and materials development.
Check Digit Verification of cas no
The CAS Registry Mumber 910462-33-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,0,4,6 and 2 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 910462-33:
(8*9)+(7*1)+(6*0)+(5*4)+(4*6)+(3*2)+(2*3)+(1*3)=138
138 % 10 = 8
So 910462-33-8 is a valid CAS Registry Number.
910462-33-8Relevant academic research and scientific papers
Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutan
Wang, Aoli,Li, Xixiang,Chen, Cheng,Wu, Hong,Qi, Ziping,Hu, Chen,Yu, Kailin,Wu, Jiaxin,Liu, Juan,Liu, Xiaochuan,Hu, Zhenquan,Wang, Wei,Wang, Wenliang,Wang, Wenchao,Wang, Li,Wang, Beilei,Liu, Qingwang,Li, Lili,Ge, Jian,Ren, Tao,Zhang, Shanchun,Xia, Ruixiang,Liu, Jing,Liu, Qingsong
, p. 8407 - 8424 (2017/11/03)
FLT3-ITD mutant has been observed in about 30% of AML patients and extensively studied as a drug discovery target. On the basis of our previous study that ibrutinib (9) exhibited selective and moderate inhibitory activity against FLT3-ITD positive AML cel
ANTIVIRAL COMPOUNDS
-
Page/Page column 442, (2014/09/29)
The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.
